Michael Schneiders, the CFO of BRAIN Biotech AG, presents a summary of the company’s Capital Markets Day highlights on the seat11a platform.
Michael introduces BRAIN Biotech AG as an industrial biotech company with offspring in the pharma and diagnostic.
Michael presents BRAIN Biotech AG’s new corporate structure in three clearly defined business pillars: the enzyme and food ingredient products business BioProducts, custom research services BioScience and the pipeline of breakthrough projects BioIncubator.
Michael shares that the company aims to create a top 10 Global multi-niche food enzyme and ingredient champion. In addition, BRAIN will aim to carve out Akribion Genomics, a genome editing platform, as a subsidiary to attract growth financing.
BRAIN Biotech AG offers critical enabling technology for the Biotransformation of the economy and has potentially discovered an innovative method to deplete cancer cells in oncology treatments.
Michael discusses how Brain Biotech addresses the megatrends of healthier and more sustainable food production. He believes industrialized countries will move increasingly away from livestock farming and find alternative protein sources, which Brain Biotech is happy to help produce through fermentation and precise fermentation.
Brain Biotech is wholly integrated into its value chain, allowing them to produce alternative proteins immaculate, healthy, and reasonable.
Michael shares BRAIN Biotech AG’s ambition to become a top 10 enzyme player globally within five years, doubling their current product revenue from around 40 million to about 80 million.
They are looking for high organic growth in the group and to achieve a 15% (+/- 5PP) group EBITDA margin, 20% for products within five years.
They plan to become a multi-niche player and the partner of choice for their global customer base.
BRAIN Biotech AG already has an international production footprint and plans to expand its production capacity significantly. Finally, Michael talks about Brain Biotech’s yet-to-be-founded subsidiary, Akribion Genomics, and their vision of attracting external growth capital.
March 6, 2023
16:50 
seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG
Reviews for BRAIN Biotech AG Deep Dive 2021 | Revolutionizing the Food & Healthcare Industries with CFO